Treating deeper skin tones safely — what changes?

For patients with Fitzpatrick skin types IV–VI — the scale that classifies skin by melanin content and photosensitivity, from type I (always burns, never tans) to type VI (deeply pigmented, never burns) — device selection and settings are a patient safety issue, not a preference. The primary risk is post-inflammatory hyperpigmentation (PIH): excess melanin production triggered by epidermal thermal injury that can produce darkening more persistent and harder to treat than the original concern. The devices that minimize this risk are those that reduce the thermal load on the melanin-rich epidermis — specifically longer-wavelength lasers such as Nd:YAG 1064 nm, and energy modalities that bypass the epidermis entirely, such as RF microneedling. Settings, test spots, and provider experience complete the picture: the right device at the wrong settings still causes harm.

Why darker skin tones carry higher risk — the PIH mechanism

Melanin is the skin's primary chromophore — the molecule that absorbs light energy. In Fitzpatrick types IV–VI, melanin is present in higher concentrations and distributed more diffusely across all epidermal layers, not only the basal layer. When a light-based or heat-generating device delivers wavelengths that melanin absorbs efficiently, that energy converts to heat in the epidermis. If the thermal load exceeds what melanocytes can tolerate, they respond with upregulated melanin synthesis — the PIH response. The consequence is a new pigmentation problem created in the process of treating an existing one.

Superficial PIH — confined to the epidermis — typically fades within weeks to a few months with diligent sun protection and topical brightening agents. Dermal PIH, where melanin is deposited in the dermis rather than the epidermis, can persist for 12–24 months or longer and is substantially harder to treat. The clinical priority is prevention: selecting the device and settings that avoid triggering PIH in the first place is more reliable than managing it after the fact. The Fitzpatrick assessment before any energy treatment is not paperwork — it is the step that determines whether the treatment plan is appropriate.

Which devices are safer — and the physics behind the choice

Melanin's absorption coefficient decreases as wavelength increases — meaning longer-wavelength devices deposit proportionally less energy into surface melanin and more into the intended target tissue deeper in the skin. The clinical consequence is a more favorable epidermal safety profile. Nd:YAG 1064 nm is the benchmark: its wavelength passes through the epidermis with low melanin absorption and targets chromophores at depth, making it the standard of care for laser hair removal and vascular treatment across Fitzpatrick types IV–VI. Non-ablative fractional devices at 1550 nm or 1927 nm can be used in deeper skin tones with conservative fluence (energy per unit area, measured in J/cm²), reduced density, and more sessions to distribute the same cumulative effect over a longer, safer course.

Shorter-wavelength devices carry the reverse problem. Alexandrite at 755 nm, KTP at 532 nm, and ruby at 694 nm have high melanin absorption coefficients — the wavelengths where epidermal damage risk is substantially elevated in types IV–VI. IPL (intense pulsed light), which emits a broad spectrum including shorter wavelengths, carries significant PIH risk without extensive filtering and conservative settings, and is generally not recommended for darker skin tones without careful device selection. Ablative CO₂ (10,600 nm) and Er:YAG (2940 nm) produce dramatic surface resurfacing results but require aggressive epidermal injury to do so — the PIH risk in types IV–VI is high enough that these devices are used only under highly controlled conditions, with a test spot, or avoided entirely. RF microneedling occupies a different category: radiofrequency energy is delivered dermally through insulated needles, bypassing the epidermis and its melanin content entirely. This makes it one of the most inclusive options for texture, scarring, and laxity across the full Fitzpatrick range.

Conservative settings, test spots, and what oversight means here

Even with the right device, settings determine the safety margin. Fluence, pulse duration, spot size, and number of passes all affect how much thermal energy reaches the epidermis. For deeper skin tones, the standard approach is lower fluence, longer pulse durations (which spread thermal energy over time rather than concentrating it in a single peak), and fewer passes — accepting more sessions to achieve the same cumulative result in exchange for a lower per-session risk. This is not a conservative choice made for lack of confidence; it is the clinically correct risk-management framework for this skin biology.

Test spots — applying treatment to a small, inconspicuous area 4–6 weeks before a full session and assessing the skin response — are standard practice for first-time patients with Fitzpatrick types IV–V and near-universal for type VI. If the test spot produces erythema that persists beyond the expected recovery window or shows early PIH signs, settings are adjusted before full treatment proceeds. Pre-treatment priming with topical brightening agents — hydroquinone, kojic acid, azelaic acid, or a retinoid — is often prescribed for 4–6 weeks before energy treatments to suppress melanocyte reactivity and reduce PIH risk; this is a medical prescription decision, not a skincare add-on. These calibration choices — wavelength selection, fluence, test-spot timing, priming protocol — require both device-specific technical knowledge and judgment about individual skin behavior. This is precisely the category where physician oversight is not a regulatory formality; it is the mechanism by which a safe outcome is distinguished from a harmful one.

Common questions

This is general information, not medical advice; device selection, settings, and candidacy are determined by a licensed provider at consultation.